The strategies employed for the treatment of ER+ breast cancer target estrogen receptor signaling in the cell with the use of selective ER modulators (SERMS, e.g., tamoxifen), selective ER down regulators (SERDs, e.g., fulvestrant), or estrogen synthesis with aromatase inhibitors (AI, e.g., anastrozole) [14,15]. This evidence concerns the gene CYP19A1 and breast carcinoma.